Views & Analysis | Perspectives on pharma industry issues

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

R&D

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.

Digital

Patient access will not improve without better digital found...

Digital health cannot succeed without infrastructure that supports it at every level.

Digital

The SPR must be built for the health system to come

The creation of a Single Patient Record (SPR) is one of the most significant reforms to health data in a generation.

Views & Analysis

Specialty pharma’s next big opportunity: it’s time for patie...

In January 2020, the financial conglomerate Visa

Views & Analysis

What makes a good (and bad) pharmaceutical forecast model

Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts can result in decisions which are commercially damaging to organisations.

Events

Anthropy 2022

Between the 2nd and 4th November, a veritable who’s who of British industry will gather at the Eden Project in Boldeva, Cornwall for Anthropy 2022, the event’s second year.

Sales & Marketing

Why trust is becoming pharma’s most important visibility met...

Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.

Sales & Marketing

Pharma is marketing to the wrong mind

On the benefits of instinctive marketing, over either rational or emotional.

Digital

Prescribed, but never filled: Why patient access is broken

Patient access is no longer just an administrative backroom function; it is a core determinant of health outcomes.

Digital

Patient access will not improve without better digital found...

Digital health cannot succeed without infrastructure that supports it at every level.

Market Access

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Preparing for the pharma fraud enforcement surge

Here is what robust, risk-based compliance looks like in 2026.

Oncology

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Oncology

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Patients